Abstract
There has been a steady growing trend during the last few decades to develop tools to monitor periodontitis, in the field of oral disease diagnosis. Since GCF has the chance of being closely approximated to the periodontal tissues where periodontal disease begins, it seems to provide more information than markers in saliva. In response to bacterial infection, host production of inflammatory mediators, may be the trigger for periodontal disease progression. Existing paradigms in the biology of periodontitis have supported the detection of elevated levels of these mediators in GCF. This article is the Part II of the review that deals with inflammatory mediators and host-response modifiers as the potential biomarkers present in gingival crevicular fluid (GCF) and the chair side point-of-care diagnostic aids applicable to monitor periodontal inflammation.
Keywords: Biomarkers, Inflammatory mediators, Host response modifiers
Introduction
Periodontal disease is a chronic bacterial infection characterized by persistent inflammation, connective tissue breakdown and alveolar bone destruction. In addition to local periodontal tissue involvement, chronic infection of periodontium with continuous up-regulation of pro-inflammatory responses and immune mediators may contribute to systemic sequel including diabetes, pre term low birth weight babies, lung inflammation, arthritis and cardiovascular diseases. These contributing inflammatory mediators have been detected in the gingival tissues; gingival crevice fluid (GCF) of patients affected by periodontitis, and qualitative changes in the composition of these biomarkers could have a diagnostic and therapeutic significance.
Table 1.
Cytokines |
---|
Interleukin -1 a |
Interleukin -1β |
Interleukin -1 ra |
Interleukin-2 |
Interleukin-6 |
Interleukin-8 |
Tumor necrosis factor a |
Interferon a |
Prostaglandin E2 |
Leukotriene B4 |
Acute-phase proteins |
Lactoferrin |
Transferrin |
a2 -Macroglobulin |
a 1-Proteinase inhibitor |
C-reactive protein |
Autoantibodies |
Anti-desmosomal antibody |
Antibacterial antibodies |
IgG1, IgG2 , IgG3 , IgG4 |
IgM |
IgA |
Plasminogen activator (PA) |
PA inhibitor-2 (PAI-2) |
Substance P |
Vasoactive intestinal peptide |
Neurokinin A |
Neopterin |
Platelet -Activating Factor |
CDl4 |
Cystatins |
Calgranulin A (MRP-8) |
Cytokines - Lipopolysaccharide (LPS) is a key microbial stimulus that will trigger the host response at periodontal disease sites. It is a cell-wall component of gram-negative bacteria, shed out of the biofilm in membrane vesicles. Locally, it triggers monocytes to release inflammatory mediators (Prostaglandin E2, Thromboxane B, Interleukins -1, -6 and -8, Tumor necrosis factor) that increase the local destruction of the connective tissues structural elements. Therefore, levels of monocytic inflammatory mediators (including prostaglandin E2, interleukin-1, and tumor necrosis factor) in GCF may well represent the ideal markers of disease activity at a site level [1-6].
Interleukin-1 (IL-1) is a potent bone-resorbing cytokine formerly known as the osteoclast-activating factor. Interleukin-1 is primarily produced by activated macrophages or lymphocytes but it may also be released by other cells, including mast cells, fibroblasts, keratinocytes, endothelial cells and its production is stimulated by bacterial lipopolysaccharide [7]. It is found in two active forms IL-1α and IL-1β. Once secreted, IL-1 may activate lymphocytes, incite macrophage chemotaxis and prostaglandin production, and stimulate osteoclastic resorption of bone [8]. IL-1 has been detected in both periodontal tissues and GCF in patients with periodontal disease [9]. Interleukin-6 is an inflammatory cytokine that leads to bone remodeling [10]. Tumor necrosis factor - α is produced by activated macrophages in response to bacterial LPS. It has similar effects on osteoclast as IL-1 but is less potent. Both IL-1 and TNF-α induce production of proteinases in mesenchymal cells, including MMPs, which contribute to connective tissue destruction [11].
IL-1, IL-6, and TNF- α are found in significant concentrations in GCF from periodontally diseased sites. Reductions in IL-1 concentrations are associated with successful treatment [12]. Elevated levels of IL-6 in GCF are associated with sites that do not respond well in initial nonsurgical phases of therapy [13]. Increasing severity of periodontitis is associated with increased concentrations of IL-1 and decreasing concentrations of IL-1ra [14]. Preliminary findings also suggest a possible inverse relationship between TNF-α [4] and IFN-γ [5] and a positive relationship between IL-6 [6] and tissue inflammation, however appropriate longitudinal studies relating their presence and concentration in GCF to active periodontitis have yet to be conducted.
IL-8 was originally described as a chemotactic protein isolated from stimulated human blood mononuclear cells. This cytokine is induced and secreted from many different cells, including monocytes, lymphocyte, fibroblasts, endothelial cells, epithelial cells and synovial cells. IL-8 is a potentially important mediator regulating PMN activity in the crevicular environment. This cytokine induces shape change, chemotaxis, a rise in intracellular free calcium, the respiratory burst, and exocytosis of primary and secondary granules from these cells. In addition, IL-8 can induce adhesion of PMN to endothelial cells, transendothelial migration of these cells as well as up-regulation of complement receptors 1 and 3 (CR1 and CR3) on the surface of human PMN [15]. Decreased IL-8 concentrations at diseased sites may reflect the reduced anti-bacterial host defense activity at that site [16].
Interferon α - It is thought to promote anti-bacterial IgG activity. Since IL-1 may promote Th 1 activity through increased IL-2 production, IL-1 may also increase IFN- α production. Also, since IFN- α is produced by Th 1 cells and Th 1 cells are responsible for cell-mediated immune responses. A decrease in the effective GCF concentrations of IFN- α at diseased sites may signify a lowered cell-mediated immune response, which may result in decreased specific anti-periodontopathic bacterial activity [17].
lL-2 has primarily been associated with an autocrine factor for T cells,[18] although recent data indicate the ability of this factor to stimulate B lymphocytes, a report by Pilon et al. [19] provided evidence for IL-2 in GCF, suggesting activation of T lymphocytes in the periodontium.
RANTES - It is a member of a superfamily of proinflammatory cytokines, activates monocytes, eosinophil and basophilic leukocytes, [20] inducing chemotaxis and the release of other cell mediators [21]. This chemokine is involved in the development of the gingival inflammatory response by mediating the recruitment and activation of leukocytes. RANTES is present in GCF of patients with periodontitis and is undetectable in healthy subjects [22].
Prostaglandin E2 - Prostaglandins are synthesized by most mammalian cells and have been implicated as components of the inflammatory reaction, being able to produce vasodilatation, bone resorption and inhibition of collagen synthesis. The primary cells responsible for PGE2 production in the periodontium are macrophages and fibroblasts. It is elevated in GCF from periodontally diseased sites demonstrating inflammation and attachment loss [23].
Leukotriene B4 (LTB4) - It is a membrane derived lipid mediator formed from arachidonic acid via the 5-lipoxygenase enzymatic pathway, possesses a variety of biological actions during inflammatory response [24]. It is produced from a variety of cells including neutrophils, macrophages, and eosinophils. LTB4 plays a unique functional role by its effects on neutrophils. This potent lipid mediator can activate neutrophil chemotaxis, aggregation, and adhesion to endothelial cells; lysosomal enzyme release; and superoxide production. It increases vascular permeability, [24] and can modulate lymphocyte functions by stimulating INF-γ and IL-2 production from T cells, and increase IL-1 synthesis by monocytes. All of these LTB4-dependent mechanisms may contribute to the inflammation and destruction of the bone and connective tissue in periodontal disease. Increased LTB4 levels in GCF and periodontal tissues samples of periodontally diseased sites suggest that this lipid mediator is important in regulating inflammatory responses in the human periodontal tissues [25].
Acute-phase proteins
Lactoferrin (Lf)- is an iron-binding multifunctional glycoprotein present in most biological secretions and in neutrophils. One of the earliest and very well documented functions of Lf is the antibacterial effect against representative periodontopathic bacteria, Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and Prevotella intermedia [26]. The mechanism of the antibacterial activity of Lf is complex and several lines of evidence indicate that beside iron chelating, it involves a direct action on bacteria and/or the activation of the immune system. T sai et al. [27] found that GCF lactoferrin levels in chronic periodontitis patients were higher than in periodontally healthy individuals.
Transferrin- TF is a serum derived iron binding glycoprotein whose main function in humans is the transport of iron between sites of absorption, storage, utilization and excretion [28]. In GCF, it might function as an antibacterial agent by producing an iron-limiting environment and its levels are significantly increased during diseased state [29].
C-reactive protein (CRP) - Although produced by hepatocytes, there is evidence that CRP is present on cells associated with acute connective tissue inflammation [30]. Rapid and dramatic rise in blood levels of CRP occurs following trauma or disease producing inflammation. Its physiological role is to bind to phosphocholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via the C1Q complex [31]. The rapid rise of CRP in serum occurs following exposure to interleukin-1 [30], which is a potent bone resorber, also found in GCF. High levels of CRP are associated with chronic and aggressive periodontal diseases.
Antidesmosomal antibodies - During periodontal disease, the cells of junctional epithelium attempt to establish and maintain cell-cell contact. To promote contact, the desmosomes, specialized electron dense plaques, cement extracellular regions of cell membranes together. Interactions between desmosomal proteins are important in the formation of the desmosomes and the maintenance of stable cell adhesion [32]. Adhesion between epithelial cells may be destabilized during inflammation. Alteration in cytokeratin expression in inflamed gingiva may affect the formation of desmosomes, making the desmosomes more sensitive to inflammation-mediated proteolysis or reactive with autoantibodies. In periodontal disease, autoantibodies may be produced by antigen-specific and polyclonal activation of lymphocytes [33]. If they are expressed in periodontal disease, autoantibodies against desmosomal components may inhibit the assembly of desmosomes in the junctional epithelium. New cell-cell contact would be inhibited and apical migration of the epithelial attachment may be promoted. The presence of elevated titers of anti-desmosomal antibodies in GCF appears to distinguish periodontitis from unaffected sites [34].
Antibacterial antibodies - GCF accumulates serum immunoglobulins from the dense plasma cell infiltrate present during the established stages of periodontitis. As many patients with periodontitis, especially those with the aggressive forms, produce antibodies to infecting periodontopathic bacteria, many attempts have been made to find an association between the presence of antibodies in GCF and periodontitis.
IgG antibodies have been considered important in preventing periodontal destruction in patients with aggressive and chronic periodontitis. IgG is composed of four distinct subclasses. The IgG subclasses differ not only in their distribution in normal serum, but also in their biologic properties and the nature of the antigens, which elicit their production [35]. One important biologic function of IgG involves the activation of the complement cascade, which can initiate a number of protective reactions including phagocyte chemotaxis, membranolytic attack on susceptible gram-negative organisms, immune adherence, and opsonization. Whereas IgG1 and IgG3 are potent complement activators, IgG2 is comparatively weak in this regard. IgG4 appears to be inactive in fixing complement via the classical pathway. IgG2 is the major immunoglobulin subclass that reacts with bacterial carbohydrates and lipopolysaccharides, and it may serve as a good opsonin [36]. An impairment of IgG2 responses may increase the risk of bacterial disease including periodontal disease. In periodontal lesions, IgG-positive plasma cells predominate, which is reflected in IgG, being the primary immunoglobulin in GCF in advanced clinical stages of periodontitis [37].
IgM antibodies exert anti-bacterial activities by enzyme, toxin and viral neutralization, complement-induced cytolysis, agglutination, opsonization and inhibition of attachment to host tissue. It is less numerous but are first to be released in the presence of an antigen [38]. Mean amount of IgM in GCF was significantly greater at baseline than at 3 months after root planning and scaling [39].
IgA in GCF may have anti-inflammatory effects. It has been demonstrated to be a potent inhibitor of complement activation by IgG [40]. In the gingival sulcus, IgA could function by preventing adherence of pathologic microorganisms to the tooth surface and thereby helping to eliminate these bacteria from the subgingival environment. IgA may also function by binding directly to IgA specific Fc receptors on PMN, which in turn could down regulate the activity of these cells [41]. Concentration of IgA is elevated in patients with less severe periodontal disease. This elevated concentration of IgA suggests that it may play an important protective mechanism in the periodontium and furthermore, it may be useful in identifying patients who are protected, or at low risk for future periodontal disease [42].
Plasminogen activator (PA) and PA inhibitor-2 (PAI-2) - The fibrinolytic system is important in inflammatory reactions in that it regulates pericellular proteolysis. This may facilitate connective tissue breakdown and spread of inflammatory lesions. The system is activated by plasminogen activators (PA), which are serine proteases catalyzing the conversion of the inactive proenzyme plasminogen into the active enzyme plasmin. Plasmin is an aggressive enzyme, which can in turn activate procollagenases and other metalloproteases [43], thereby participating in the tissue destruction seen at inflammatory lesions. PAs can be produced by several types of cells, among them, macrophages [44]. The activity of the PAs is balanced by two similarly distinct, specifically acting plasminogen activator inhibitors (PAI-1 and PAI-2). Both PAs and PAI are found in GCF in notably high concentrations, from inflamed gingival sites compared to healthy sites [45]. Within the range of gingival inflammation studied, the PAs seemed to be balanced by a higher concentration of PAI-2, since no change was seen in the molar ratio of PAs to PAI-2 [46].
Substance P and Neurokinin A - Neuropeptides are biologically active peptides generated primarily in neurons. Substance P (SP) and neurokinin A (NKA) are members of the tachykinin family of neuropeptides. SP and NKA are derived from the same gene, may have very similar roles [47], but have distinct receptors [48]. SP and NKA are stored in secretory granules of sensory unmyelinated c-type fibers and significant amounts are present both in primary sensory neurones and in their peripheral branches [49]. Antidromic stimulation leads to the release of these peptides from the peripheral nerve endings which can lead to vasodilatation, increased microvascular permeability and plasma extravasation, resulting in neurogenic inflammation [50]. Experimental studies have demonstrated that the application of SP can cause neurogenic inflammation of the oral mucosa [51]. Immunohistochemical studies have shown that SP is localized in nerve fibers of gingival connective tissue [52]. The release of these peptides into the gingival connective tissue could be followed by the diffusion through the epithelium and subsequently into the gingival crevice or periodontal pocket [53].
Vasoactive intestinal peptide (VIP) – It is a ubiquitous peptide, with a multiplicity of actions, including modulation of both natural and acquired immunity [54]. Although VIP affects a variety of immune functions, its primary immunomodulatory function is anti-inflammatory in nature. Two sources of VIP have been described, nerves (both central and peripheral) and leukocytes. Nerve fibers positive for VIP have been identified in gingival tissue from both normal and periodontitis-affected sites [55]. Periodontal treatment results in changes in the levels of the proinflammatory neuropeptides SP and NKA in GCF [56]. In periodontitis subjects, VIP is significantly elevated in periodontitis-affected sites compared with the levels in clinically healthy sites. Non-surgical periodontal treatment in these patients resulted in an improvement in the periodontal condition, accompanied by a reduction in the levels of VIP in periodontitis sites compared to those found in clinically healthy sites [57].
Neopterin - It is an actual molecular mass compound belonging to the class of pteridines, is an early and valuable biomarker of cellular immunity. Neopterin is produced by human macrophages after the induction by IFN- γ secreted by T lymphocytes which play an important role in periodontal diseases [58]. Ozmeric et al. [59] have reported that GCF neopterin concentration is higher in periodontitis patients.
Platelet Activating Factor (PAF) - It is a potent biologically active phospholipid mediator capable of exerting marked proinflammatory responses [60]. Major cell sources for the production of PAF are thrombocytes, neutrophils, macrophages, eosinophils, and epithelial cells [60]. It is linked to many inflammatory and immune responses including platelet stimulation, neutrophil and monocyte activation, increased vascular permeability, and smooth muscle contraction. PAF activates IL-1 production by monocytes, inhibits IL-2 synthesis from T lymphocytes, and modulates B-cell functions [60]. All of these PAF-dependent mechanisms may contribute to the destruction of the bone and connective tissue in periodontal disease together with other host-derived mediators. Overall, elevated PAF levels in both GCF and gingival tissue samples of specific periodontal diseases support the destructive role of this lipid mediator in human periodontal tissues [61].
CD14 - It was originally described as a myeloid differentiation antigen detected on mature monocytes/macrophages and neutrophils [62]. It is a key molecule responsible for the innate recognition of bacteria by host cells and functions as an important LPS receptor on monocytes/macrophages and neutrophils [63]. CD14 exists in 2 forms, a membrane-bound form (mCD14) and a circulating soluble form (sCD14). sCD14 appears to have 2 main functions: 1) neutralizing the LPS-LBP complex, thereby preventing further stimulation of the inflammatory response, and 2) interacting with cells that do not normally express CD14, such as endothelial cells and epithelial cells, enabling LPS activation of these cells [64]. The release of cytokines IL-1β, TNF-α, and PGE2 and the expression of cell adhesion molecules such as E-selectin and ICAM-1 are all initiated in the response of host cells to CD14 complexed with microbial LPS [62]. Thus, CD14 may play an important role in the regulation of inflammatory and immunological responses, and the tissue destruction mediated by LPS in the pathogenesis of periodontitis. Increased sCD14 concentrations in GCF was found in the study by Jin and Darveau [65].
Cystatins- They comprise a superfamily of proteins, subdivided into 3 families [66]. Family 1 cystatins (cystatin A and B) are homologous 1-domain proteins of 11 kDa, which are found mainly intracellularly. Family 2 cystatins are proteins of 14 kDa and contain 2 disulfide bridges. These cystatins are found mainly in secretory fluids and are represented in saliva by acidic (S, SA), neutral (SN, D) and basic (C) cystatins [67]. Family 3 cystatins, the kininogens, are intravascular multifunctional proteins with 3 cystatin-like domains. Cystatins are the endogenous inhibitors that regulate the activity of cysteine proteinases. Cystatin activity in GCF is caused mainly by cystatin A [68].
Calgranulin A (MRP-8) - MRP-8 and MRP-14 are both expressed in circulating PMN and macrophages, but not in macrophages found in normal healthy tissue. In acute inflammatory reactions, MRP-8 is never found in the tissue, whereas in chronic inflammation, MRP-8 and MRP-14 are expressed by macrophages in the inflamed tissue [69]. MRP-8 is a major responsive protein involved in the pathogenesis of periodontitis, functioning as a powerful chemotaxin leading to further influx of PMN into the inflammatory focus in the gingival crevice/ pocket. Alternatively, evidence that MRP-8 is chemotactic for periodontal ligament cells [70] may indicate a role for MRP-8 in periodontal remodeling. MRP-8 is detectable in GCF of chronic periodontitis, without MRP-14 [71].
Chairside diagnostic kits
Molecular analysis of GCF elution can be time consuming while most of the GCF analytic assays are laboratory based and usually cannot be performed in a chair-side manner. These procedures, as well as GCF sampling, are technically demanding and the GCF volume can be very small (1-5 μl). Despite these apparent diagnostic and technical disadvantages, GCF is still considered as a candidate potential oral fluid for the development of adjunctive non-invasive chair-side point of-care diagnostic technology, especially because tissue destructive MMPs and their bioactive regulators can conveniently be measured by distinct catalytic and non-catalytic immunoassays from GCF.
Table 2.
ASSAY | KIT | MANUFACTURER/SUPPLIER | FUNCTION |
---|---|---|---|
Bacterial enzymes & host enzymes | BANA periodontal test | Ora Tec Corporation Manassas (USA) | It utilizes the BANA test for bacterial trypsin like proteases |
Periocheck (ASTech) [72] | CollaGenex Pharmaceuticals, Newtown, PA | Detects presence of neutral proteinases i.e. Collagenase | |
PerioScan | Oral B Laboratories | Detects enzymatic activity of Aggregatibacter actinomycetemcomitans, T forsythus, P gingivalis | |
Immunological detection | Evalusite | Kodak Eastman Company (Switzerland) | Immunological detection of antigens of Aggregatibacter actinomycetemcomitans, P intermedia, P gingivalis using antibodies (ELISA) |
Biochemical Identification | Prognostic [72] | Dentsply | Aids in detection of serine proteinases and elastases |
Biolise [73] | SLT-Labinstruments, Crailsheim, Germany | Aids in detection of elastase | |
Periogard [74] | Colgate | Detects the presence of AST | |
Pocket watch | SteriOss®, San Diego, CA, USA | Detects aspartate aminotransferase through colorimetric detection | |
TOPAS | Affinity Labelling Technologies (USA) | Detects toxins derived from anaerobic metabolism and measures GCF protein level |
Future directions for biomarker based diagnostics of periodontitis
Through the biomarker discovery process, new therapeutics have been designed linking therapeutic and diagnostic approaches together, especially in the area of host modulatory drugs for periodontal disease treatment. Moreover, new diagnostic technologies, such as microarray and microfluidics, are now currently available for risk assessment and comprehensive screening of biomarkers. The future is bright for the use of rapid, easy-to-use diagnostics that will provide an enhanced patient assessment that can guide and transform customized therapies for dental patients, leading to more individualized, targeted treatments for oral health.
Conclusion
Periodontal tissue destruction derived from chronic periodontitis occurs as consequence to the activation of immune-inflammatory response of the host to bacterial challenge. Major events comprise pro-inflammatory cytokine production and collagenolytic MMPs leading to soft periodontal tissue breakdown. These cytokines along with bone MMPs, will lead ultimately to octeoclastogenesis and alveolar bone resorption. Qualitative and/or quantitative changes in oral fluid biomarkers might be useful as adjunctive diagnostics and treatment of periodontitis.
References
- 1.Kamma J, Mombelli A, Tsinidou K. Cytokines in gingival crevicular fluid of adolescents and young adults. Cytokines in gingival crevicular fluid of adolescents and young adults. Oral Microbiol Immunol. 2009;24:7–10. doi: 10.1111/j.1399-302X.2008.00466.x. [DOI] [PubMed] [Google Scholar]
- 2.Sanders AE, Slade GD, Fitzsimmons TR. Physical activity, inflammatory biomarkers in gingival crevicular fluid and periodontitis. J Clin Periodontol. 2009;36:388–395. doi: 10.1111/j.1600-051X.2009.01394.x. [DOI] [PubMed] [Google Scholar]
- 3.Charon JA, Luger TA, Mergenhagen SE. Increased thymocyte-activating factor in human gingival fluid during gingival inflammation. Infect Immun. 1982;38:1190–1195. doi: 10.1128/iai.38.3.1190-1195.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Rossomando EF, Kennedy JE. Tumour necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol. 1990;35:431–434. doi: 10.1016/0003-9969(90)90205-o. [DOI] [PubMed] [Google Scholar]
- 5.Grbic JT, Mannick JA. The role of prostaglandin E2 in immune suppression following injury. Ann Surg. 1991;214:253–263. doi: 10.1097/00000658-199109000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Geivelis M, Turner DW. Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol. 1993;64:980–983. doi: 10.1902/jop.1993.64.10.980. [DOI] [PubMed] [Google Scholar]
- 7.Page RC. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodontal Res. 1991;26:230–242. doi: 10.1111/j.1600-0765.1991.tb01649.x. [DOI] [PubMed] [Google Scholar]
- 8.Alexander MB, Damoulis PD. The role of cytokines in the pathogenesis of periodontal disease. Curr Opin Periodontol. 1994:39–53. [PubMed] [Google Scholar]
- 9.Al-Shammari KF, Giannobile WV. Effect of non-surgical periodontal therapy on C-telopeptide pyridinoline cross-links (ICTP) and interleukin-1 levels. J Periodontol. 2001;72:1045–1051. doi: 10.1902/jop.2001.72.8.1045. [DOI] [PubMed] [Google Scholar]
- 10.Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115–137. doi: 10.1210/edrv.21.2.0395. [DOI] [PubMed] [Google Scholar]
- 11.Graves DT. The potential role of chemokines and inflammatory cytokines in periodontal disease progression. Clin Infect Dis. 1999;28:482–490. doi: 10.1086/515178. [DOI] [PubMed] [Google Scholar]
- 12.Macuch PJ, Tanner AC. Campylobacter species in health, gingivitis and periodontitis. J Dent Res. 2000;79:785–792. doi: 10.1177/00220345000790021301. [DOI] [PubMed] [Google Scholar]
- 13.Masada MP, Persson R. Measurement of interleukin-1 alpha and -1 beta in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. J Periodontal Res. 1990;25:156–163. doi: 10.1111/j.1600-0765.1990.tb01038.x. [DOI] [PubMed] [Google Scholar]
- 14.Rawlinson A, Dalati MH. Interleukin-1 and IL-1 receptor antagonist in gingival crevicular fluid. J Clin Periodontol. 2000;27:738–743. doi: 10.1034/j.1600-051x.2000.027010738.x. [DOI] [PubMed] [Google Scholar]
- 15.Chung RM, Grbíc JT. Interleukin-8 and beta-glucuronidase in gingival crevicular fluid. J Clin Periodontol. 1997;24:146–152. doi: 10.1111/j.1600-051x.1997.tb00483.x. [DOI] [PubMed] [Google Scholar]
- 16.Tsai CC, Ho YP. Levels of interleukin-1 beta and interleukin-8 in gingival crevicular fluids in adult periodontitis. J Periodontol. 1995;66:852–859. doi: 10.1902/jop.1995.66.10.852. [DOI] [PubMed] [Google Scholar]
- 17.Mathur A, Michalowicz B. Interleukin-1 alpha, interleukin-8 and interferon-alpha levels in gingival crevicular fluid. J Periodontal Res. 1996;31:489–495. doi: 10.1111/j.1600-0765.1996.tb01414.x. [DOI] [PubMed] [Google Scholar]
- 18.Abbas AK, Lichtman AH, compilers. In: Cellular and Molecular Immunology. Philadelphia: Saunders; 1991. pp. 225–243. [Google Scholar]
- 19.Pilon M, Williams-Miller C. Interleukin 2 levels in gingival crevicular fluid in periodontitis. J Dent Res. 1991;70:550. [Google Scholar]
- 20.Murphy PM. Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev. 1996;7:47–64. doi: 10.1016/1359-6101(96)00009-3. [DOI] [PubMed] [Google Scholar]
- 21.Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today. 1994;15:127–133. doi: 10.1016/0167-5699(94)90156-2. [DOI] [PubMed] [Google Scholar]
- 22.Gamonal J, Bascones A. Chemokine RANTES in gingival crevicular fluid of adult patients with periodontitis. J Clin Periodontol. 2000;27:675–681. doi: 10.1034/j.1600-051x.2000.027009675.x. [DOI] [PubMed] [Google Scholar]
- 23.Masada MP, Persson R. Measurement of interleukin-1 alpha and -1 beta in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. J Periodontal Res. 1990;25:156–163. doi: 10.1111/j.1600-0765.1990.tb01038.x. [DOI] [PubMed] [Google Scholar]
- 24.Ford-Hutchinson AW. Leukotriene B4 in inflammation. Crit Rev Immunol. 1990;10:1–12. [PubMed] [Google Scholar]
- 25.Emingil G, Cinarcik S. Levels of leukotriene B4 in gingival crevicular fluid and gingival tissue in specific periodontal diseases. J Periodontol. 2001;72:1025–1031. doi: 10.1902/jop.2001.72.8.1025. [DOI] [PubMed] [Google Scholar]
- 26.Wakabayashi H, Kondo I. Periodontitis, periodontopathic bacteria and lactoferrin. Biometals. 2010;23:419–424. doi: 10.1007/s10534-010-9304-6. [DOI] [PubMed] [Google Scholar]
- 27.Tsai CC, Kao CC. Gingival crevicular fluid lactoferrin levels in adult periodontitis patients. Aust Dent J. 1998;43:40–44. doi: 10.1111/j.1834-7819.1998.tb00151.x. [DOI] [PubMed] [Google Scholar]
- 28.Aisen P, compiler. In: Transferrins. In: Jacobs A, Worwood M. Iron in Biochemistry and Medicine. London: Academic Press; 1971. pp. 29–71. [Google Scholar]
- 29.Curtis MA, Gillett IR. Detection of high-risk groups and individuals for periodontal diseases: laboratory markers from analysis of gingival crevicular fluid. J Clin Periodontol. 1989;16:1–11. doi: 10.1111/j.1600-051x.1989.tb01604.x. [DOI] [PubMed] [Google Scholar]
- 30.Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med. 1992;37:313–336. [PubMed] [Google Scholar]
- 31.Thompson D, Pepys MB. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169–177. doi: 10.1016/S0969-2126(99)80023-9. [DOI] [PubMed] [Google Scholar]
- 32.Pasdar M, Nelson WJ. Regulation of desmosome assembly in epithelial cells: kinetics of synthesis, transport, and stabilization of desmoglein I, a major protein of the membrane core domain. J Cell Biol. 1989;109:163–177. doi: 10.1083/jcb.109.1.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Anusaksathien O, Singh G. Autoimmunity to collagen in adult periodontal disease: immunoglobulin classes in sera and tissue. J Periodontal Res. 1992;27:55–61. doi: 10.1111/j.1600-0765.1992.tb02086.x. [DOI] [PubMed] [Google Scholar]
- 34.Govze Y, Herzberg MC. Serum and gingival crevicular fluid anti-desmosomal antibodies in periodontitis. J Periodontol. 1993;64:603–608. doi: 10.1902/jop.1993.64.7.603. [DOI] [PubMed] [Google Scholar]
- 35.Farida R, Wilson M. Serum IgG antibodies to lipopolysaccharides in various forms of periodontal disease in man. Arch Oral Biol. 1986;31:711–715. doi: 10.1016/0003-9969(86)90001-4. [DOI] [PubMed] [Google Scholar]
- 36.Al-Ghamdi HS, Anil S. Serum antibody levels in smoker and non-smoker saudi subjects with chronic periodontitis. J Periodontol. 2007;78:1043–1050. doi: 10.1902/jop.2007.060431. [DOI] [PubMed] [Google Scholar]
- 37.Brajović G, Stefanović G. Association of fibronectin with hypogalactosylated immunoglobulin G in gingival crevicular fluid in periodontitis. J Periodontol. 2010;81:1472–1480. doi: 10.1902/jop.2010.100053. [DOI] [PubMed] [Google Scholar]
- 38.Hodges K, compiler. In: Concepts in Nonsurgical Periodontal Therapy. 1st ed. New York: Delmar Cengage Learning; 1997. pp. 19–89. [Google Scholar]
- 39.Sengupta S, Lamster IB. The Effect of treatment on IgG, IgA,IgM and α-2-Macroglobulin in gingival crevicular fluid from patients with chronic adult periodontitis. Archs Oral Biol. 1988;33:425–431. doi: 10.1016/0003-9969(88)90200-2. [DOI] [PubMed] [Google Scholar]
- 40.Waldo FB, Cochran AM. Mixed IgA-IgG aggregates as a model of immune complexes in IgA nephropathy. J Immunol. 1989;142:3841–3846. [PubMed] [Google Scholar]
- 41.Saito K, Kato C. IgA-mediated inhibition of human leucocyte function by interference with Fc gamma and C3b receptors. Immunology. 1991;74:99–106. [PMC free article] [PubMed] [Google Scholar]
- 42.Grbic JT, Singer RE. Immunoglobulin isotypes in gingival crevicular fluid: possible protective role of IgA. J Periodontol. 1998;66:55–61. doi: 10.1902/jop.1995.66.1.55. [DOI] [PubMed] [Google Scholar]
- 43.Vassalli JD, Pepper MS. Tumour biology: Membrane proteases in focus. Nature. 1994;370:14–15. doi: 10.1038/370014a0. [DOI] [PubMed] [Google Scholar]
- 44.Manchanda N, Schwartz BS. Lipopolysaccharide-induced modulation of human monocyte urokinase production and activity. J Immunol. 1990;145:4174–4180. [PubMed] [Google Scholar]
- 45.Kinnby B, Matsson L. Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid. J Periodontal Res. 1996;31:271–277. doi: 10.1111/j.1600-0765.1996.tb00493.x. [DOI] [PubMed] [Google Scholar]
- 46.Kinnby B, Matsson L. The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis. Scand J Dent Res. 1994;102:334–341. [PubMed] [Google Scholar]
- 47.Wiesenfeld-Hallin Z, Xu XJ. The differential roles of substance P and neurokinin A in spinal cord hyperexcitability and neurogenic inflammation. Regul Pept. 1993;46:165–173. doi: 10.1016/0167-0115(93)90027-6. [DOI] [PubMed] [Google Scholar]
- 48.Nakanishi S, Nakajima Y. Signal transduction and ligand-binding domains of the tachykinin receptors. Regul Pept. 1993;46:37–42. doi: 10.1016/0167-0115(93)90009-w. [DOI] [PubMed] [Google Scholar]
- 49.Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol. 1995;45:1–98. doi: 10.1016/0301-0082(94)e0017-b. [DOI] [PubMed] [Google Scholar]
- 50.Pernow , compiler. In: Research on Taehykinins: Clinical Trends. In: Henry JL. Substance P and Neurokinins. New York: Springer; 1987. pp. 373–379. [Google Scholar]
- 51.Györfi A, Fazekas A. Role of substance P (SP) in development of symptoms of neurogenic inflammation in the oral mucosa of the rat. J Periodontal Res. 1993;28:191–196. doi: 10.1111/j.1600-0765.1993.tb01068.x. [DOI] [PubMed] [Google Scholar]
- 52.Luthman J, Johansson O. Immunohistochemical studies of the neurochemical markers, CGRP, enkephalin, galanin, gamma-MSH, NPY, PHI, proctolin, PTH, somatostatin, SP, VIP, tyrosine hydroxylase and neurofilament in nerves and cells of the human attached gingiva. Arch Oral Biol. 1988;33:149–158. doi: 10.1016/0003-9969(88)90039-8. [DOI] [PubMed] [Google Scholar]
- 53.Linden GJ, McKinnell J. Substance P and neurokinin A in gingival crevicular fluid in periodontal health and disease. J Clin Periodontol. 1997;24:799–803. doi: 10.1111/j.1600-051x.1997.tb01192.x. [DOI] [PubMed] [Google Scholar]
- 54.Bellinger DL, Lorton D. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol. 1996;6:5–27. doi: 10.1016/s0960-5428(96)00008-3. [DOI] [PubMed] [Google Scholar]
- 55.Luthman J, Friskopp J. Immunohistochemical study of neurochemical markers in gingiva obtained from periodontitis-affected sites. J Periodontal Res. 1989;24:267–278. doi: 10.1111/j.1600-0765.1989.tb01792.x. [DOI] [PubMed] [Google Scholar]
- 56.Lundy FT, Mullally BH. Changes in substance P and neurokinin A in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol. 2000;27:526–530. doi: 10.1034/j.1600-051x.2000.027007526.x. [DOI] [PubMed] [Google Scholar]
- 57.Linden GJ, Mullally BH. Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol. 2002;29:484–489. doi: 10.1034/j.1600-051x.2002.290602.x. [DOI] [PubMed] [Google Scholar]
- 58.Werner-Felmayer G, Baier-Bitterlich G. Detection of bacterial pyrogens on the basis of their effects on gamma interferon-mediated formation of neopterin or nitrite in cultured monocyte cell lines. Clin Diagn Lab Immunol. 1995;2:307–313. doi: 10.1128/cdli.2.3.307-313.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Ozmeriç N, Baydar T. Level of neopterin, a marker of immune cell activation in gingival crevicular fluid, saliva, and urine in patients with aggressive periodontitis. J Periodontol. 2002;73:720–725. doi: 10.1902/jop.2002.73.7.720. [DOI] [PubMed] [Google Scholar]
- 60.Denizot Y, Dupuis F. Effects of platelet-activating factor on human T and B cells--an overview. Res Immunol. 1994;145:109–116. doi: 10.1016/s0923-2494(94)80021-9. [DOI] [PubMed] [Google Scholar]
- 61.Emingil G, Cinarcik S. Levels of platelet-activating factor in gingival crevicular fluid and gingival tissue in specific periodontal diseases. J Periodontol. 2001;72:1032–1037. doi: 10.1902/jop.2001.72.8.1032. [DOI] [PubMed] [Google Scholar]
- 62.Haziot A, Tsuberi BZ. Neutrophil CD14: biochemical properties and role in the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide. J Immunol. 1993;150:5556–5565. [PubMed] [Google Scholar]
- 63.Wright SD. CD14 and innate recognition of bacteria. J Immunol. 1995;155:6–8. [PubMed] [Google Scholar]
- 64.Frey EA, Miller DS. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med. 1992;176:1665–1671. doi: 10.1084/jem.176.6.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Jin L, Darveau RP. Soluble CD14 levels in gingival crevicular fluid of subjects with untreated adult periodontitis. J Periodontol. 2001;72:634–640. doi: 10.1902/jop.2001.72.5.634. [DOI] [PubMed] [Google Scholar]
- 66.Barrett AJ, Fritz H. Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J. 1986;236:312. doi: 10.1042/bj2360312. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Henskens YM, Veerman EC. Cystatins in health and disease. Biol Chem Hoppe Seyler. 1996;377:71–86. doi: 10.1515/bchm3.1996.377.2.71. [DOI] [PubMed] [Google Scholar]
- 68.Blankenvoorde MF, Henskens YM. Cystatin A in gingival crevicular fluid of periodontal patients. J Periodontal Res. 1997;32:583–588. doi: 10.1111/j.1600-0765.1997.tb00935.x. [DOI] [PubMed] [Google Scholar]
- 69.Zwadlo G, Brüggen J. Two calcium-binding proteins associated with specific stages of myeloid cell differentiation are expressed by subsets of macrophages in inflammatory tissues. Clin Exp Immunol. 1988;72:510–515. [PMC free article] [PubMed] [Google Scholar]
- 70.Nishimura F, Terranova VP. Comparative study of the chemotactic responses of periodontal ligament cells and gingival fibroblasts to polypeptide growth factors. J Dent Res. 1996;75:986–992. doi: 10.1177/00220345960750041401. [DOI] [PubMed] [Google Scholar]
- 71.Lundy FT, Chalk R. Identification of MRP-8 (calgranulin A) as a major responsive protein in chronic periodontitis. J Pathol. 2000;192:540–544. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH740>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
- 72.Page RC. Host response tests for diagnosing periodontal disease. J Periodontol. 1992;63:356–366. doi: 10.1902/jop.1992.63.4s.356. [DOI] [PubMed] [Google Scholar]
- 73.Hermann JM, Gonzales JR. Microassay for the detection of elastase activity in the gingival crevice. J Clin Periodontol. 2001;28:31–37. doi: 10.1034/j.1600-051x.2001.280105.x. [DOI] [PubMed] [Google Scholar]
- 74.Eley BM, Cox SW. Advances in periodontal diagnosis, Commercial diagnostic tests based on GCF proteolytic and hydrolytic enzyme levels. Br Dent J. 1998;184:373–376. doi: 10.1038/sj.bdj.4809636. [DOI] [PubMed] [Google Scholar]